Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, Juan Carlos Hinojosa, Nicola Kerr, Maria Rosario, Stephen Toovey, Robert H. Arch, Margaret A. Phillips, Felix D. Rozenberg, Jade Bath, Caroline L. Ng, Annie N. Cowell, Elizabeth A. Winzeler, David A. Fidock, Mark Baker, Jörg J. Möhrle, Rob Hooft van Huijsduijnen, Nathalie Gobeau, Nada AraeipourNicole Andenmatten, Thomas Rückle, Stephan Duparc

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

95 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science